Ind-Swift Labs. Q1 FY27 Results (NSE: INDSWFTLAB)
Signal: Steady quarter
The read
The operating recovery is strengthening: consolidated revenue grew 25.4% YoY, EBITDA grew 126.0% and EBITDA margin reached 21.5%, extending the rebound from the 2.4% OPM recorded in Q1FY26; the next proof point is whether the Viatris, Manx and Arrotex CDMO commercialization and regulated-market investments convert the margin recovery into recurring revenue rather than relying on ₹7.65 Cr of other income.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹191.45 Cr | 25.4% | N/A |
| EBIT | ₹33.5 Cr | 191.1% | |
| Net profit | ₹24.68 Cr | 181.4% | |
| EPS | ₹2.84 | 121.9% | |
| EBIT margin | 21.5% |
P&L walk
Consolidated revenue was ₹191.45 Cr, up 25.4% YoY, while EBITDA grew 126.0% and EBITDA margin reached 21.5%; EBIT rose 191.1% and PAT 181.4%, with the bottom line also supported by ₹7.65 Cr of other income.
Segments
No segment results table was disclosed; standalone PAT of ₹24.44 Cr versus consolidated PAT of ₹24.68 Cr shows that the parent contributes virtually all reported group profit.
Key positives
- Consolidated EBITDA grew 126.0% YoY to ₹41.09 Cr and EBITDA margin reached 21.5%, indicating substantial operating recovery from the 2.4% OPM recorded in Q1FY26.
- The finished-dosage and CDMO transition is gaining commercial traction, with the Viatris, Manx and Arrotex partnership expected to add ₹200-220 Cr of FY27 revenue.
- Dossiers increased to 2,100+ from 1,915+ earlier and product registrations rose to 900+ from 750+, expanding the future commercialization pipeline.
- Two products reached commercialization during the quarter: Ibuprofen Sachet for Europe and Macrogol Sachet for the UK and Australia.
Key concerns
- FY27 revenue guidance of more than 50% requires a significant acceleration from Q1FY27 consolidated growth of 25.4% YoY.
- The planned Samba EU-GMP and PIC/S upgrade has strategic relevance for regulated-market and CDMO growth, but the investment amount and timing were not disclosed.
- Consolidated EPS grew 121.9% YoY versus PAT growth of 181.4%, requiring monitoring for dilution or changes in minority interests.
Earnings quality: includes non-operating other income
Research and educational content only. Not investment advice.